Evaluatepharma: the orphan drug market will reach 176 billion US dollars in 2020, BMS or transnovartis

Source: medical economic report 2014-11-19 in recent years, the research and development heat of orphan drugs has not decreased The scale of clinical trials for rare diseases is often small, and there is a lack of treatment options, which brings advantages to the regulatory review of orphan drugs In addition, the preferential tax policy further reduces the R & D cost When orphan drugs enter the market, their average price is six times that of non orphan drugs, and their pricing ability is very outstanding A recent orphan drug research report released by evaluatepharma, a huge market of 176 billion US dollars, shows that its sales growth rate shows no sign of slowing down By 2020, orphan drug sales will account for 19% of the total sales of prescription drugs, reaching 176 billion US dollars According to the forecast, the annual compound growth rate of the drug sales scale identified as orphan drugs by the regulatory authorities of the United States, Europe and Japan by 2020 is close to 11%, while the annual growth rate of the drugs used to treat large patient groups is only about 4% The report said there was no sign of a slowdown in research on orphan drug indications in the pharmaceutical industry Although the U.S revised Orphan Drug Act, in order to prevent pharmaceutical companies from improperly defining orphan drug indications, it became cautious in terms of words, but this did not affect the development of orphan drugs As the number of newly defined indications for orphan drugs increases, so will the number of orphan drugs that have successfully completed clinical trials and registered In addition, although the pricing environment for orphan drugs is still favorable, consumers will pay more attention to the management of drug expenses Because after the expiration of drug patents in the next few years, the growing drug price will slow down And as more orphan drugs come on the market, insurance companies will pay close attention to new ways to stop the cost growth Especially with the implementation of the reasonable medical expenses act in the United States, the number of people receiving medical subsidies will continue to increase At that time, it is expected that the huge cost of orphan drug research and development will encounter greater pressure BMS replaces Novartis in the previous report, pointing out that due to the rapid growth of cancer immunotherapy drug opdivo, Bristol Myers Squibb is expected to surpass Novartis in the next six years and become the largest orphan drug company by 2020 At that time, Bristol Myers Squibb's orphan drug sales will reach US $11.1 billion, of which US $6 billion comes from opdivo In addition, celgene's Revlimid sales are stable, ranking third with $10.4 billion in 2020 Pharmacyclics, on the other hand, is in the top 20 on its single drug, imbruvica For the ranking of other global pharmaceutical giants, Roche dropped 2 places, ranking 4th; Pfizer dropped 1, ranking 5th; GlaxoSmithKline rose 6 places, ranking 9th Evaluate Pharma, the sales champion of lenalidomide, predicted that lenalidomide would be the world's highest sales orphan drug in 2020, with sales reaching 8 billion US dollars The drug was approved for marketing in November 2005, and is the first drug for myelodysplastic syndrome in the world In addition, it has been approved for the treatment of rare non Hodgkin's lymphoma and multiple myeloma, and several indications are under development Bristol Myers Squibb, which is used to treat multiple myeloma and Hodgkin's lymphoma opdivo, is expected to become the world's second largest orphan drug with sales of US $6 billion.